Search clinical trials for: Raynaud Phenomenon refractory to treatment

Total 475038 results

Emory University
American Society for Surgery of the Hand

Recruiting

Botulinum Toxin in Raynaud's Phenomenon

Raynaud Phenomenon

United States
Peter Korsten
DiaMed GmbH

Recruiting

Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis (RHEACT)

Systemic Sclerosis | Scleroderma | Raynaud Phenomenon | Digital Ulcer

Germany
University of Minnesota

Withdrawn

Phototherapy For Treatment Of Raynaud's Phenomenon

Raynaud Disease | Raynaud Phenomenon | Raynaud Syndrome

United States
University of Toledo Health Science Campus
ElectroCore INC

Terminated

Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.

Raynaud Disease | Raynaud Phenomenon | Primary Raynaud Phenomenon | Raynaud Syndrome

United States
Michiel Kuijpers

Completed

Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study

Raynauds

Netherlands
Southern Illinois University

Completed

A Two-Part Study of BOTOX® Therapy for Ischemic Digits

Raynaud's Disease

United States
Lawson Health Research Institute
Delivra, Inc.

Withdrawn

Tadalafil-Delivra and Raynaud's Phenomenon

Raynaud Phenomenon

Canada
Pfizer

Completed

PF-00489791 For The Treatment Of Raynaud's

Peripheral Vascular Disease | Raynaud's Disease

Spain, United States, Czechia, Hungary, Poland, Korea, Republic of, Canada, Mexico, Germany, Colombia, Sweden
Primus Pharmaceuticals

Completed

Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease

United States
Pontificia Universidad Catolica de Chile

Completed

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Lupus Erythematosus, Systemic | Dermatomyositis | Ultrasound Therapy; Complications | Raynaud Disease | Raynaud Phenomenon Due to Trauma | System; Sclerosis

Chile
Northwestern University
Eli Lilly and Company

Completed

Tadalafil for the Treatment of Raynaud's

Raynaud

United States
Johns Hopkins University

Completed

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Scleroderma | Raynaud

United States
University of Michigan

Completed

Acupressure for the Treatment of Raynaud's Phenomenon

Primary Raynaud's Phenomeon

United States
Seoul National University Hospital
Dong-A Pharmaceutical Co., Ltd.

Completed

Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

Raynaud Phenomenon

Korea, Republic of
MediQuest Therapeutics

Unknown

Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms

Raynaud Disease

United States
MediQuest Therapeutics

Unknown

A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Raynaud's Disease | Raynaud's Disease Secondary to Scleroderma | Raynaud's Disease Secondary to Other Autoimmune Disease

United States
Lawson Health Research Institute

Completed

St. John's Wort in the Treatment of Raynaud's Phenomenon

Raynaud's Disease

Canada
MediQuest Therapeutics

Completed

Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon

Raynaud's Disease

United States
MediQuest Therapeutics

Completed

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Raynaud's Disease

United States, Canada
MediQuest Therapeutics

Completed

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Raynaud's Disease | Raynaud's Disease Secondary to Scleroderma | Raynaud's Disease Secondary to Autoimmune Disease

United States
MediQuest Therapeutics

Completed

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

Autoimmune Diseases | Scleroderma | Raynaud's Disease

United States, United Kingdom, Sweden
Otsuka America Pharmaceutical

Completed

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease

United States
Otsuka America Pharmaceutical

Completed

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Raynaud's Disease

United States
Neurona Therapeutics

Not yet recruiting

Effect of NRTX-1001, a Cellular Therapy Product, for the Treatment of Refractory Bilateral TLE

Epilepsy, Temporal Lobe
Mayo Clinic

Not yet recruiting

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Mannkind Corporation

Not yet recruiting

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension (ICoN-1)

Mycobacterium Infections, Nontuberculous | MAC Lung Disease | Treatment Refractory MAC Lung Disease

United States
Zhejiang University
Gracell Biotechnology Shanghai Co., Ltd.

Recruiting

An Exploratory Clinical Study of GC012F Injection for the Treatment of Refractory Generalized Myasthenia Gravis

Refractory Generalized Myasthenia Gravis

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Not yet recruiting

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Rheumatoid Arthritis | Systemic Lupus Erythematosus | Systemic Sclerosis | Immune Thrombocytopenia | Sjogren's Syndrome | Idiopathic Inflammatory Myopathies | Primary Biliary Cholangitis
Wuxi People's Hospital

Recruiting

Low-dose Chemotherapy Under Hypoglycaemia for the Treatment of Relapsed Refractory Advanced Solid Tumours

Solid Tumors, Adult

China
Wuhan Union Hospital, China
ITabMed Co., Ltd.

Not yet recruiting

Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML

Refractory Acute Myeloid Leukemia | Conditioning | Hematopoietic Stem Cell Transplantation | Relapse Leukemia
Mayo Clinic

Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
Changzhou No.2 People's Hospital

Not yet recruiting

An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma

Multiple Myeloma

China
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Shanghai Unicar-Therapy Bio-medicine Technology...
Peking University People's Hospital; The First Affiliated Hospital of Soochow...

Not yet recruiting

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Relapsed or Refractory Acute Lymphoblastic Leukemia

China
Peking University People's Hospital

Not yet recruiting

Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD

cGVHD
PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Recruiting

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis | Idiopathic Inflammatory Myopathies | Primary Sjögren Syndrome | IgG4 Related Disease

China
Xuanwu Hospital, Beijing

Not yet recruiting

Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome

Tourette's Syndrome

China
China Medical University Hospital

Recruiting

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Hepatocellular Carcinoma

Taiwan
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
Guangzhou Bio-gene Technology Co., Ltd

Not yet recruiting

BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children

Acute Myeloid Leukemia | Leukemia
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer (NOTABLE-308)

Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Jonsson Comprehensive Cancer Center

Not yet recruiting

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

Diffuse Hemispheric Glioma, H3 G34-Mutant

United States
Changzhou No.2 People's Hospital
Rui Therapeutics Co., Ltd

Not yet recruiting

An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia

Thrombocytopenia Alloimmune
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Heart Rhythm Clinical and Research Solutions, LLC
Biosense Webster, Inc.

Recruiting

The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. (QDOT PAS)

Paroxysmal Atrial Fibrillation

United States

Search clinical trials for: Raynaud Phenomenon refractory to treatment

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations